Interaction Checker

Dasatinib interactions

Dasatinib (Sprycel, Phyrago) has 152 documented interactions across the FDA labels and fact sheets we index: 69 major, 30 moderate, 53 minor, and 0 where a label reports no significant interaction. Each entry below quotes the sentence behind it. This drug page is a starting point, not a verdict for your situation.

Interactions from the label

Major interactions (69)

  • AmiodaroneantiarrhythmicMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Antacids (Tums, Maalox, Mylanta)OTC productMajor

    Antacids: Avoid concomitant use. (Dasatinib label, Drug interactions)

  • AprepitantCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • ArmodafinilCNS stimulantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • AtazanavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • BosentanCYP3A4 inducerMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • CarbamazepineanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • CenobamateanticonvulsantMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • CimetidineH2 blockerMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Clarithromycinmacrolide antibioticMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • ClobazambenzodiazepineMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • CyclosporineimmunosuppressantMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • DarunavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Darunavir and cobicistatantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Deferasiroxiron supplementMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • DexamethasonecorticosteroidMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Diltiazemcalcium channel blockerMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • DronedaroneantiarrhythmicMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • EfavirenzantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Efavirenz, lamivudine, and tenofovirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Elvitegravir, cobicistat, emtricitabine, and tenofovirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Erythromycinmacrolide antibioticMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • EslicarbazepineanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • EtravirineantiretroviralMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • EverolimusimmunosuppressantMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Fluconazoleazole antifungalMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • FosamprenavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • FosaprepitantCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • FosphenytoinanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • GriseofulvinantifungalMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Ibuprofen and famotidineNSAIDMajor

    Intervention Concomitant administration of ibuprofen and famotidine tablet is not recommended with dasatinib, delavirdine mesylate, cefditoren, and fosamprenavir. (Ibuprofen and famotidine label, Drug interactions)

  • ImatinibCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • IsoniazidantibioticMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Itraconazoleazole antifungalMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • IvacaftorCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Ketoconazoleazole antifungalMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • LenacapavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Lopinavir and ritonavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • LorlatinibCYP3A4 inducerMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • MifepristoneCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Mirabegronbeta-adrenergic agonistMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • MitapivatCYP3A4 inducerMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • MitotaneCYP3A4 inducerMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • ModafinilCNS stimulantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Nafcillinpenicillin antibioticMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • NefazodoneantidepressantMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • NevirapineantiretroviralMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Nirmatrelvir and ritonavirantiviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Omeprazole and sodium bicarbonateproton pump inhibitorMajor

    Antacids: Avoid concomitant use. (Dasatinib label, Drug interactions)

  • OxcarbazepineanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • PalbociclibCYP3A4 inhibitorMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • PerampanelanticonvulsantMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • PhenobarbitalbarbiturateMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Phentermine and topiramateCNS stimulantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • PhenytoinanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Posaconazoleazole antifungalMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • PrimidoneanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • RanolazineQT-prolonging drugMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • RifabutinantibioticMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • RifampinantibioticMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • RifapentineantibioticMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • RitonavirantiretroviralMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Sodium bicarbonateantacidMajor

    Antacids: Avoid concomitant use. (Dasatinib label, Drug interactions)

  • Suvorexantsedative-hypnoticMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • SuzetrigineCYP3A4 inducerMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Ticagrelorantiplatelet agentMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • TopiramateanticonvulsantMajor

    If concomitant administration of a strong CYP3A4 inducer cannot be avoided, consider a dose increase [see Dosage and Administration ( 2.3 )] . (Dasatinib label, Drug interactions)

  • Verapamilcalcium channel blockerMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

  • Voriconazoleazole antifungalMajor

    Avoid concomitant use of strong CYP3A4 inhibitors. (Dasatinib label, Drug interactions)

Moderate interactions (30)

  • AdenosineantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • ApixabananticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • ArgatrobananticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • BivalirudinanticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • DabigatrananticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • Dexlansoprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Dexlansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Dexlansoprazole label, Drug interactions)

  • Digoxindigitalis glycosideModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • DisopyramideantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • DofetilideantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • EdoxabananticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • EnoxaparinanticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • Esmololbeta blockerModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • Esomeprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Esomeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity Intervention: Mycophenolate mofetil (MMF): Co-administration of omeprazole, of which esomeprazole… (Esomeprazole label, Drug interactions)

  • FlecainideantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • FondaparinuxanticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • HeparinanticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • IbutilideantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • Lansoprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Lansoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Lansoprazole label, Drug interactions)

  • Lidocainelocal anestheticModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • Lidocaine and prilocainelocal anestheticModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • MexiletineantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • Omeprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Omeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Omeprazole label, Drug interactions)

  • Pantoprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole/itraconazole) Clinical Impact: Pantoprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Pantoprazole label, Drug interactions)

  • ProcainamideantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • PropafenoneantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • QuinidineantiarrhythmicModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • Rabeprazoleproton pump inhibitorModerate

    Drugs Dependent on Gastric pH for Absorption (e.g., iron salts, erlotinib, dasatinib, nilotinib, mycophenolate mofetil, ketoconazole, itraconazole) Clinical Impact: Rabeprazole can reduce the absorption of other drugs due to its effect on reducing intragastric acidity. (Rabeprazole label, Drug interactions)

  • RivaroxabananticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

  • Sotalolbeta blockerModerate

    QT Prolongation PHYRAGO may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy [see Adverse Reactions ( 6.1 )] . (Dasatinib label, Warnings and precautions)

  • WarfarinanticoagulantModerate

    Use caution if used concomitantly with medications that inhibit platelet function or anticoagulants. (Dasatinib label, Warnings and precautions)

Minor mentions (53)

  • Acetazolamidecarbonic anhydrase inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Amiloridepotassium-sparing diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Atenolol and chlorthalidonebeta blockerMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Azelastine and fluticasoneantihistamineMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • BeclomethasonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Benazepril and hydrochlorothiazideACE inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • BetamethasonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Bisoprolol and hydrochlorothiazidebeta blockerMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • BudesonidecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Budesonide and formoterolcorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Bumetanideloop diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Candesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Chlorothiazidethiazide diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Chlorthalidonethiazide diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • CiclesonidecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • ClobetasolcorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • DeflazacortcorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • DesonidecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Enalapril and hydrochlorothiazideACE inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Eplerenonealdosterone antagonistMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Ethacrynic acidloop diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • FludrocortisonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • FlunisolidecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • FluocinonidecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • FluticasonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Fluticasone and salmeterolcorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Fosinopril and hydrochlorothiazideACE inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Furosemideloop diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • HalobetasolcorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Hydrochlorothiazidethiazide diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • HydrocortisonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Indapamidethiazide diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Irbesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Lisinopril and hydrochlorothiazideACE inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Losartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • MethylprednisolonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Metolazonethiazide diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Metoprolol and hydrochlorothiazidebeta blockerMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • MometasonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Olmesartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Olmesartan, amlodipine, and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Olopatadine and mometasoneantihistamineMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • PrednisolonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • PrednisonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Quinapril and hydrochlorothiazideACE inhibitorMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Spironolactonealdosterone antagonistMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Spironolactone and hydrochlorothiazidealdosterone antagonistMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Telmisartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Torsemideloop diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • TriamcinolonecorticosteroidMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Triamterenepotassium-sparing diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Triamterene and hydrochlorothiazidepotassium-sparing diureticMinor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

  • Valsartan and hydrochlorothiazideangiotensin II receptor blocker (ARB)Minor

    Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (Dasatinib label, Warnings and precautions)

Check Dasatinib against everything you take. Add your full list; every pair is checked at once.

Open in the checker

Not medical advice. Severity reflects the label's wording, not your circumstances. A "major" flag can be routine under supervision and a "minor" one can matter at high doses. Ask a pharmacist.